Recent studies have focused on the overlap of GLP|glucose-dependent insulinotropic polypeptide|glucagon receptor agonist therapies and dopamine neurotransmission. While GLP agonists are increasingly employed for addressing type 2 T2DM, their unexpected effects on reinforcement circuits, specifica